🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT05924477
Recruiting Not applicable

Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial

NCT05924477 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2023-07-11
Last updated
2026-07-14

Condition(s) studied

Glaucoma

Investigational drug(s) / intervention(s)

Sulcus tube placementAnterior chamber (AC) tube placement

Sulcus tube placement: GDD implantation surgery with tube placement in the ciliary sulcus

Anterior chamber (AC) tube placement: GDD implantation surgery with tube placement in the anterior chamber

Study summary

Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Medically uncontrolled glaucoma requiring GDD or GDD combined with phacoemulsification as the planned surgical procedure * Candidate for GDD implantation for ciliary sulcus and AC tube * Age greater than or equal to 18 years old Exclusion Criteria: * Preexisting corneal condition that would affect the corneal endothelium or previous corneal transplant * Presence or history of Cypass Micro-Stent * Previous GDD, Xen Gel Stent or Preserflo MicroShunt removed less than 6 months before surgery * Presence of GDD implantation, Xen Gel Stent, of Preserflo MicroShunt * Previous trabeculectomy and/or minimally invasive glaucoma surgery within the past 6 months * AC intraocular lens * Presence of nanophthalmos, uncontrolled uveitis, silicone oil, Sturge-Weber syndrome or other conditions associated with elevated episcleral venous pressure * Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits * No light perception vision in the study eye or fellow eye visual acuity \< 20/200 * Need for glaucoma surgery combined with other ocular procedures (i.e. corneal transplant, or retinal surgery) or anticipated need for additional ocular surgery

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
University of California San Francisco San Francisco California Recruiting
Diablo Eye Associates Walnut Creek California Recruiting
Bascom Palmer Eye Institute Miami Florida Recruiting
Wilmer Eye Institute, Johns Hopkins University Baltimore Maryland Recruiting
Massachusetts Eye and Ear Boston Massachusetts Recruiting
University of Buffalo/State University of New York Buffalo New York Recruiting
University of North Carolina at Chapel Hill Chapel Hill North Carolina Recruiting
Prism Eye Institute, University of Toronto Toronto Canada Recruiting

More University of Pennsylvania trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05924477 on ClinicalTrials.gov ↗ ← All trials in Canada